The aromatase inhibitors in early breast cancer: who, when, and why?

Area of Science:

• Endocrinology
• Oncology
• Pharmacology

Background:

• Aromatase inhibitors deplete oestrogen by inhibiting the aromatase enzyme.
• They are indicated for hormone-receptor-positive breast cancer in postmenopausal women.
• Tamoxifen and aromatase inhibitors serve as adjuvant therapies with comparable efficacy in the initial 5 years.

Purpose of the Study:

• To evaluate aromatase inhibitors as an alternative to tamoxifen.
• To assess the benefits of switching to aromatase inhibitors after tamoxifen therapy.
• To compare the side effect profiles of aromatase inhibitors and tamoxifen.

Main Methods:

• Comparative analysis of adjuvant therapy efficacy.
• Evaluation of treatment switching strategies.
• Assessment of adverse event profiles including hot flushes, endometrial toxicity, venous thromboembolism, arthralgia, myalgia, and bone fracture.

Main Results:

• Aromatase inhibitors and tamoxifen show similar efficacy in the first 5 years of adjuvant therapy.
• Switching to aromatase inhibitors after 2-5 years of tamoxifen may benefit high-risk patients.
• Aromatase inhibitors are associated with more hot flushes and bone fractures but less endometrial toxicity and venous thromboembolism compared to tamoxifen.

Conclusions:

• Aromatase inhibitors are a viable alternative to tamoxifen, particularly for patients with intolerance or contraindications.
• Switching therapy post-tamoxifen warrants consideration for high-risk individuals.
• Understanding the distinct side effect profiles is crucial for patient management and treatment selection.